WHWK NASDAQ
Whitehawk Therapeutics Inc
1W: +4.4%
1M: -11.4%
3M: -9.0%
YTD: +36.5%
1Y: +38.2%
3Y: -18.6%
5Y: -87.5%
$3.33
+0.19 (+6.05%)
Weekly Expected Move ±8.3%
$3
$3
$3
$3
$4
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 14.08.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
17 relationships17
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-05-17
Earliest Filing
2025-03-26
Latest Filing
partner: 7
acquirer: 5
supplier: 3
customer: 1
target: 1
Counterparties (Filed by WHWK)
17 relationshipsCompanies named in WHWK's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| KAKEN INVESTMENTS INC. | — | acquirer | Purchased 100% of Aadi Subsidiary, Inc. for $102.4 million | 2025-03-26 | View |
| KAKEN PHARMACEUTICAL CO., LTD | — | acquirer | Co-signatory to the Stock Purchase Agreement for the acquisition of Aadi Subsidiary, Inc. | 2025-03-26 | View |
| KAKEN INVESTMENTS INC. | — | acquirer | Acquired 100% of Aadi Subsidiary, Inc. and all assets related to the FYARRO Business. | 2025-03-04 | View |
| KAKEN INVESTMENTS INC. | — | acquirer | Acquired 100% of Aadi Subsidiary, Inc. for $100 million | 2024-12-20 | View |
| KAKEN PHARMACEUTICAL CO., LTD. | — | partner | Guaranteed Purchaser's obligations under the Stock Purchase Agreement | 2024-12-20 | View |
| WuXi Biologics (Shanghai FX) Co., Ltd. | — | partner | Granted exclusive license for antibody drug conjugate programs | 2024-12-20 | View |
| Hangzhou DAC Biotechnology Co., Ltd. | — | partner | Owner of linker payload technology licensed to WuXi Biologics | 2024-12-20 | View |
| Jefferies LLC | JEF | partner | Acted as exclusive placement agent for the PIPE Financing | 2024-12-20 | View |
| Fresenius Kabi, LLC | — | supplier | Amendment to purchase order agreement for FYARRO® product supply | 2024-04-04 | View |
| Cowen and Company, LLC | — | partner | Sales agent for an at-the-market offering of common stock | 2022-03-17 | View |
| Fresenius Kabi, LLC | — | supplier | Agreement for Fresenius Kabi to manufacture Fyarro for Aadi Bioscience, Inc. | 2022-01-20 | View |
| Abraxis BioScience, LLC | — | partner | Licensee in exclusive worldwide license agreement for ABI-009 | 2021-09-03 | View |
| Bristol Myers Squibb Company | CELG-RI | partner | Parent company of Abraxis BioScience, LLC | 2021-09-03 | View |
| BRE Sunset Coast, LLC | — | supplier | Landlord in corporate headquarters lease agreement | 2021-09-03 | View |
| EyePoint Pharmaceuticals, Inc. | EYPT | customer | Aerpio sold patents and patent applications for razuprotafib and Tie2 antibodies to EyePoint in exchange for a $450,000 | 2021-08-23 | View |
| Aadi Bioscience, Inc. | AADI | target | Target company in the merger agreement with Aerpio Pharmaceuticals, Inc. | 2021-05-17 | View |
| Aspen Merger Subsidiary, Inc. | ASPU | acquirer | Wholly-owned subsidiary of Aadi used as the merger vehicle. | 2021-05-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-10 | Officer/Director Change; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-12 | Shareholder Vote | View | |
| 2026-05-21 | Other Events; Exhibits | View | |
| 2026-05-13 | Material Agreement; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-31 | Financial Statements and Exhibits | View | |
| 2025-03-26 | Completion of Acquisition or Disposition of Assets; Financial Statements and Exhibits | Acquisition | View |
| 2025-03-18 | Results of Operations and Financial Condition; Amendments to Articles of Incorporation or Bylaws; Fi | View | |
| 2025-03-04 | Entry into Material Definitive Agreement; Submission of Matters to a Vote of Security Holders; Regul | Agreement | View |
| 2024-12-20 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-19 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-08-22 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-08-21 | Costs Associated with Exit or Disposal Activities; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR